Panagora Asset Management Inc. Reduces Holdings in Gilead Sciences, Inc. $GILD

Panagora Asset Management Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.5% during the fourth quarter, HoldingsChannel reports. The fund owned 1,245,653 shares of the biopharmaceutical company’s stock after selling 321,348 shares during the quarter. Panagora Asset Management Inc.’s holdings in Gilead Sciences were worth $152,891,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quattro Advisors LLC purchased a new position in shares of Gilead Sciences during the 4th quarter worth about $26,000. Ares Financial Consulting LLC bought a new position in Gilead Sciences during the 4th quarter valued at about $28,000. Financial Consulate Inc. raised its position in Gilead Sciences by 85.8% in the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 109 shares during the period. North Star Investment Management Corp. lifted its stake in Gilead Sciences by 54.8% in the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 86 shares during the last quarter. Finally, BOCHK Asset Management Ltd bought a new stake in Gilead Sciences in the fourth quarter worth about $31,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen, a potentially important catalyst for Gilead’s HIV franchise and long-term growth. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Bernstein reiterated a Buy view on Gilead, and unusual call option activity suggests traders are positioning for upside ahead of additional catalysts. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: The company advanced a Phase 2 study of denikitug in difficult-to-treat colorectal cancer, adding another pipeline readout that could broaden Gilead’s oncology prospects. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Positive Sentiment: Gilead is donating remdesivir to Uganda to support Ebola response efforts, reinforcing the company’s reputation in infectious disease care and public-health leadership. Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
• Neutral Sentiment: Gilead and the Gilead Foundation announced about $3 million in funding with the National AIDS Memorial for HIV/AIDS education and leadership initiatives, a brand-building effort with limited near-term earnings impact. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
• Neutral Sentiment: Erste Group slightly lowered its FY2026 earnings estimate for Gilead, but the revision was small and stays close to the broader loss expectations already in place. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Negative Sentiment: Recent commentary suggests Gilead’s stock has pulled back from its 50-day and 200-day moving averages, indicating some short-term technical pressure despite the positive pipeline news.

Insider Buying and Selling

In related news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the transaction, the insider owned 125,779 shares of the company’s stock, valued at $16,513,524.91. The trade was a 18.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $131.46, for a total value of $1,971,900.00. Following the sale, the chief executive officer owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 62,000 shares of company stock valued at $8,182,190 over the last 90 days. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $125.59 on Monday. Gilead Sciences, Inc. has a 1-year low of $104.46 and a 1-year high of $157.29. The company has a 50-day moving average of $133.16 and a 200 day moving average of $134.34. The firm has a market cap of $155.93 billion, a PE ratio of 17.11 and a beta of 0.31. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion for the quarter, compared to the consensus estimate of $6.91 billion. During the same quarter last year, the firm posted $1.81 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be issued a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 44.69%.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Gilead Sciences in a research note on Tuesday, June 9th. Royal Bank Of Canada reissued a “sector perform” rating on shares of Gilead Sciences in a research note on Monday, June 8th. Leerink Partners dropped their price objective on Gilead Sciences from $148.00 to $146.00 in a report on Friday, May 8th. Citigroup upped their price objective on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Jefferies Financial Group initiated coverage on Gilead Sciences in a research note on Tuesday, March 10th. They issued a “buy” rating and a $180.00 target price on the stock. Twenty-five investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $156.93.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.